Abbvie (ABBV) Added to Conviction Buy List at Goldman Sachs; Analyst Sees 34% Upside
Goldman Sachs upgraded Abbvie (NYSE: ABBV) from Buy to Conviction Buy with a price target of $80.00 (from $76.00), suggesting ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)